Amgen Stock Price, News & Analysis (NASDAQ:AMGN)

$169.84 1.05 (0.62 %)
(As of 11/21/2017 04:00 PM ET)
Previous Close$168.79
Today's Range$168.89 - $170.49
52-Week Range$138.83 - $191.10
Volume2.63 million shs
Average Volume3.23 million shs
Market Capitalization$123.29 billion
P/E Ratio13.51
Dividend Yield2.71%
Beta1.37

About Amgen (NASDAQ:AMGN)

Amgen logoAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: Biotechnology
  • Sector: Healthcare
  • Symbol: NASDAQ:AMGN
  • CUSIP: 03116210
  • Web: www.amgen.com
Debt:
  • Debt-to-Equity Ratio: 1.05%
  • Current Ratio: 6.07%
  • Quick Ratio: 5.72%
Price-To-Earnings:
  • Trailing P/E Ratio: 13.51
  • Forward P/E Ratio: 13.42
  • P/E Growth: 2.46
Sales & Book Value:
  • Annual Sales: $22.99 billion
  • Price / Sales: 5.36
  • Cash Flow: $14.63 per share
  • Price / Cash: 11.61
  • Book Value: $40.16 per share
  • Price / Book: 4.23
Dividend:
  • Annual Dividend: $4.60
  • Dividend Yield: 2.7%
Profitability:
  • Trailing EPS: $11.07
  • Net Income: $7.72 billion
  • Net Margins: 35.54%
  • Return on Equity: 29.90%
  • Return on Assets: 11.80%
Misc:
  • Employees: 19,200
  • Outstanding Shares: 725,910,000
 

Frequently Asked Questions for Amgen (NASDAQ:AMGN)

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Tuesday, October 24th. Investors of record on Friday, November 17th will be given a dividend of $1.15 per share on Friday, December 8th. This represents a $4.60 annualized dividend and a yield of 2.71%. The ex-dividend date of this dividend is Thursday, November 16th. View Amgen's Dividend History.

How will Amgen's stock buyback program work?

Amgen declared that its Board of Directors has initiated a share repurchase plan on Thursday, October 26th 2017, which authorizes the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company's leadership believes its shares are undervalued.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) issued its quarterly earnings data on Wednesday, October, 25th. The medical research company reported $3.27 EPS for the quarter, topping the Zacks' consensus estimate of $3.11 by $0.16. The medical research company had revenue of $5.77 billion for the quarter, compared to analysts' expectations of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The company's revenue for the quarter was down .7% compared to the same quarter last year. During the same period in the prior year, the company earned $3.02 EPS. View Amgen's Earnings History.

When will Amgen make its next earnings announcement?

Amgen is scheduled to release their next quarterly earnings announcement on Wednesday, January, 31st 2018. View Earnings Estimates for Amgen.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY17 earnings guidance on Wednesday, October, 25th. The company provided EPS guidance of $12.50-12.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $12.56. The company issued revenue guidance of $22.7-23 billion, compared to the consensus revenue estimate of $22.86 billion.

Where is Amgen's stock going? Where will Amgen's stock price be in 2017?

20 equities research analysts have issued 12 month price targets for Amgen's shares. Their predictions range from $161.00 to $210.00. On average, they expect Amgen's share price to reach $190.67 in the next twelve months. View Analyst Ratings for Amgen.

What are Wall Street analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:

  • 1. Argus analysts commented, "We would consider a more constructive stance on AMGN on signs of stronger contributions from the company's new drug pipeline or from its biosimilars portfolio," the firm said."We note, however, that Amgen may not generate commercial revenue from biosimilars until 2019 due to regulatory and legal hurdles." (11/1/2017)
  • 2. According to Zacks Investment Research, "Amgen beat expectations for both earnings and sales in Q3 and raised its earnings guidance for 2017. However sales declined year over year. Meanwhile sales of key drug Repatha disappointed in the quarter. Amgen’s newer drugs – Prolia, Xgeva, Vectibix and Sensipar – are performing well. Amgen is also progressing with its pipeline including biosimilar drugs. Amgen’s shares have outperformed the industry this year so far. However, Amgen has some challenges in store, given the presence of biosimilar competition and slowdown in sales of mature drugs. Volume growth of new drugs may not be enough to offset the lost sales due to the decline in mature brands. While Neupogen is already facing U.S. biosimilar competition, Neulasta and Epogen could start facing the same next year. Also the softness in Enbrel sales due to stiff competitive pressure is a key cause for concern. Meanwhile, uptake of Repatha has been slow." (10/30/2017)
  • 3. Cann analysts commented, "Amgen yesterday announced that the Journal of Clinical Oncology has published positive results from the Imlygic (talimogene laherparepvec) phase II ‘264 study, demonstrating a doubling of response rate or better in the Imlygic combination arm. The data published yesterday in JCO are encouraging, and these along with results from ongoing studies could lead to unexpected adoption of Imlygic and provide upside to our sales estimates. These data demonstrated that Imlygic has a dramatic effect in combination with Yervoy, and the combination looks as strong a much of the reference data for other combinations." (10/6/2017)
  • 4. Mizuho analysts commented, "We are increasing our AMGN price target from $183 to $198 on the back of the biotech sector having re-rated somewhat post the GILD/KITE acquisition. We have not changed our estimates." (9/28/2017)
  • 5. Cowen and Company analysts commented, "Amgen reported Q1 Revenue of $5.46B (-1% Y/Y, vs. consensus of $5.61BE) and." (4/27/2017)

Who are some of Amgen's key competitors?

Who are Amgen's key executives?

Amgen's management team includes the folowing people:

  • Robert A. Bradway, Chairman of the Board, President, Chief Executive Officer (Age 54)
  • David W. Meline, Executive Vice President, Chief Financial Officer (Age 60)
  • Sean E. Harper, Executive Vice President - Research and Development (Age 54)
  • Anthony C. Hooper, Executive Vice President - Global Commercial Operations (Age 62)
  • Brian M. McNamee, Executive Vice President - Full Potential Initiatives (Age 60)
  • Esteban Santos, Executive Vice President, Operations (Age 49)
  • Cynthia M. Patton, Senior Vice President, Chief Compliance Officer (Age 55)
  • Jonathan P. Graham, Senior Vice President, General Counsel, Secretary (Age 56)
  • Lori A. Johnston, Senior Vice President (Age 52)
  • David A. Piacquad, Senior Vice President - Business Development (Age 60)

Who owns Amgen stock?

Amgen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (1.12%), Nordea Investment Management AB (0.87%), Legal & General Group Plc (0.52%), Janus Henderson Group PLC (0.44%), Schwab Charles Investment Management Inc. (0.44%) and Swiss National Bank (373,642.46%). Company insiders that own Amgen stock include Annette Louise Such, Carbonnel Francois De, Cynthia M Patton, David Baltimore, Madhavan Balachandran and Sean E Harper. View Institutional Ownership Trends for Amgen.

Who sold Amgen stock? Who is selling Amgen stock?

Amgen's stock was sold by a variety of institutional investors in the last quarter, including Flossbach Von Storch AG, Nordea Investment Management AB, Janus Henderson Group PLC, American Century Companies Inc., CI Global Investments Inc., First Eagle Investment Management LLC, State of Tennessee Treasury Department and Ameriprise Financial Inc.. Company insiders that have sold Amgen company stock in the last year include Carbonnel Francois De, Cynthia M Patton and Sean E Harper. View Insider Buying and Selling for Amgen.

Who bought Amgen stock? Who is buying Amgen stock?

Amgen's stock was acquired by a variety of institutional investors in the last quarter, including Stifel Financial Corp, Public Employees Retirement Association of Colorado, SG Americas Securities LLC, Schwab Charles Investment Management Inc., Pictet Asset Management Ltd., Amundi Pioneer Asset Management Inc., Jennison Associates LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Amgen.

How do I buy Amgen stock?

Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amgen's stock price today?

One share of Amgen stock can currently be purchased for approximately $169.84.

How big of a company is Amgen?

Amgen has a market capitalization of $123.29 billion and generates $22.99 billion in revenue each year. The medical research company earns $7.72 billion in net income (profit) each year or $11.07 on an earnings per share basis. Amgen employs 19,200 workers across the globe.

How can I contact Amgen?

Amgen's mailing address is 1 Amgen Center Dr, THOUSAND OAKS, CA 91320-1730, United States. The medical research company can be reached via phone at +1-805-4471000 or via email at [email protected]


MarketBeat Community Rating for Amgen (NASDAQ AMGN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  997 (Vote Outperform)
Underperform Votes:  611 (Vote Underperform)
Total Votes:  1,608
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Amgen (NASDAQ:AMGN)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 11 Hold Ratings, 8 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $190.67 (12.26% upside)

Consensus Price Target History for Amgen (NASDAQ:AMGN)

Price Target History for Amgen (NASDAQ:AMGN)

Analysts' Ratings History for Amgen (NASDAQ:AMGN)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/1/2017ArgusDowngradeBuy -> Hold$175.22 -> $195.00N/AView Rating Details
10/29/2017MizuhoSet Price TargetBuy$198.00N/AView Rating Details
10/26/2017BMO Capital MarketsReiterated RatingMarket Perform$198.00N/AView Rating Details
10/26/2017Morgan StanleyLower Price TargetOverweight$196.00 -> $193.00N/AView Rating Details
10/26/2017Royal Bank Of CanadaLower Price TargetSector Perform$192.00 -> $188.00N/AView Rating Details
10/13/2017Barclays PLCBoost Price TargetEqual Weight$180.00 -> $190.00N/AView Rating Details
10/6/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$203.00N/AView Rating Details
10/6/2017CannReiterated RatingBuy$203.00N/AView Rating Details
10/5/2017Bank of America CorporationBoost Price TargetBuy$210.00N/AView Rating Details
9/29/2017Credit Suisse GroupReiterated RatingNeutral$177.00 -> $186.00MediumView Rating Details
9/25/2017Jefferies Group LLCReiterated RatingBuy$200.00LowView Rating Details
7/26/2017Deutsche Bank AGReiterated RatingHold$172.00 -> $174.00LowView Rating Details
7/22/2017Cowen and CompanyReiterated RatingOutperform$209.00LowView Rating Details
6/26/2017William BlairReiterated RatingMarket PerformLowView Rating Details
6/22/2017Leerink SwannReiterated RatingMarket Perform$161.00LowView Rating Details
6/8/2017Sanford C. BernsteinSet Price TargetHold$164.00MediumView Rating Details
4/28/2017Robert W. BairdReiterated RatingNeutral$165.00LowView Rating Details
3/20/2017Goldman Sachs Group, Inc. (The)Lower Price TargetConviction-Buy$208.00 -> $202.00LowView Rating Details
3/14/2017Piper Jaffray CompaniesReiterated RatingOverweight$193.00LowView Rating Details
12/13/2016Chardan CapitalUpgradeSell -> NeutralN/AView Rating Details
9/28/2016Citigroup Inc.Lower Price TargetNeutral$175.00 -> $172.00N/AView Rating Details
9/28/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
8/26/2016GabelliInitiated CoverageHoldN/AView Rating Details
2/23/2016BTIG ResearchReiterated RatingSell$135.00N/AView Rating Details
1/22/2016Wells Fargo & CompanyReiterated RatingHoldN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$202.00N/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Amgen (NASDAQ:AMGN)

Earnings by Quarter for Amgen (NASDAQ:AMGN)

Earnings History by Quarter for Amgen (NASDAQ AMGN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/31/2018$3.02N/AView Earnings Details
10/25/2017Q3 2017$3.11$3.27$5.75 billion$5.77 billionViewN/AView Earnings Details
7/25/2017Q2 2017$3.11$3.27$5.67 billion$5.81 billionViewN/AView Earnings Details
4/26/2017Q1 2017$3.00$3.15$5.60 billion$5.46 billionViewN/AView Earnings Details
2/2/2017Q416$2.79$2.89$5.75 billion$5.97 billionViewListenView Earnings Details
10/27/2016Q316$2.79$3.02$5.73 billion$5.81 billionViewListenView Earnings Details
7/27/2016Q216$2.74$2.84$5.58 billion$5.69 billionViewListenView Earnings Details
4/28/2016Q116$2.60$2.90$5.32 billion$5.53 billionViewListenView Earnings Details
1/28/2016Q415$2.29$2.61$5.53 billion$5.54 billionViewListenView Earnings Details
10/28/2015Q315$2.38$2.72$5.32 billion$5.72 billionViewListenView Earnings Details
7/30/2015Q215$2.43$2.57$5.32 billion$5.37 billionViewListenView Earnings Details
4/21/2015Q115$2.07$2.48$4.91 billion$5.03 billionViewListenView Earnings Details
1/27/2015Q414$2.05$2.16$5.20 billion$5.33 billionViewListenView Earnings Details
10/27/2014Q314$2.11$2.30$4.95 billion$5.03 billionViewListenView Earnings Details
7/29/2014Q214$2.07$2.37$4.90 billion$5.18 billionViewListenView Earnings Details
4/22/2014Q114$1.94$1.87$4.76 billion$4.52 billionViewListenView Earnings Details
1/28/2014Q413$1.69$1.82$4.81 billion$5.01 billionViewListenView Earnings Details
10/22/2013Q313$1.78$1.94$4.60 billion$4.75 billionViewListenView Earnings Details
7/30/2013Q2 2013$1.74$1.89$4.49 billion$4.68 billionViewListenView Earnings Details
4/23/2013Q1 2013$1.84$1.96$4.37 billion$4.24 billionViewN/AView Earnings Details
1/23/2013Q4 2012$1.42$1.40$4.37 billion$4.42 billionViewListenView Earnings Details
10/23/2012$1.47$1.67ViewN/AView Earnings Details
7/26/2012$1.54$1.83ViewN/AView Earnings Details
1/26/2012$1.22$1.21ViewN/AView Earnings Details
10/24/2011$1.29$1.40ViewN/AView Earnings Details
7/29/2011$1.29$1.37ViewN/AView Earnings Details
4/20/2011$1.29$1.34ViewN/AView Earnings Details
1/24/2011$1.11$1.17ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Amgen (NASDAQ:AMGN)
2017 EPS Consensus Estimate: $12.28
2018 EPS Consensus Estimate: $12.90
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$3.04$3.17$3.09
Q2 20173$3.05$3.12$3.09
Q3 20173$3.01$3.19$3.12
Q4 20173$2.93$3.03$2.98
Q1 20182$3.29$3.30$3.30
Q2 20182$3.18$3.41$3.30
Q3 20182$3.10$3.29$3.20
Q4 20182$3.10$3.13$3.12
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Amgen (NASDAQ:AMGN)

Next Dividend:12/8/2017
Annual Dividend:$4.60
Dividend Yield:2.71%
Dividend Growth:28.60% (3 Year Average)
Payout Ratio:41.55% (Trailing 12 Months of Earnings)
36.33% (Based on This Year's Estimates)
36.19% (Based on Next Year's Estimates)
Track Record:6 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Amgen (NASDAQ:AMGN)

Dividend History by Quarter for Amgen (NASDAQ AMGN)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/24/2017quarterly$1.152.59%11/16/201711/17/201712/8/2017
7/28/2017quarterly$1.152.64%8/15/20178/17/20179/8/2017
3/7/2017quarterly$1.152.59%5/15/20175/17/20176/8/2017
12/20/2016quarterly$1.153.15%2/13/20172/15/20173/8/2017
10/14/2016quarterly$1.002.46%11/14/201611/16/201612/8/2016
7/22/2016quarterly$1.002.4%8/15/20168/17/20169/8/2016
3/2/2016quarterly$1.002.74%5/13/20165/17/20166/8/2016
12/15/2015quarterly$1.002.43%2/11/20162/16/20163/8/2016
10/14/2015quarterly$0.792.07%11/12/201511/16/201512/7/2015
7/28/2015quarterly$0.791.84%8/13/20158/17/20159/8/2015
3/4/2015quarterly$0.791.98%5/12/20155/14/20156/5/2015
12/17/2014quarterly$0.791.88%2/10/20152/12/20153/6/2015
10/17/2014quarterly$0.611.77%11/10/201411/13/201412/5/2014
7/25/2014quarterly$0.611.99%8/12/20148/14/20149/5/2014
3/5/2014quarterly$0.611.96%5/13/20145/15/20146/6/2014
12/13/2013quarterly$0.612.18%2/11/20142/13/20143/7/2014
10/16/2013quarterly$0.471.62%11/12/201311/14/201312/6/2013
7/26/2013quarterly$0.471.72%8/14/20138/16/20139/6/2013
3/6/2013quarterly$0.472.02%5/14/20135/16/20136/7/2013
12/13/2012quarterly$0.472.11%2/11/20132/13/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Amgen (NASDAQ AMGN)

Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 78.15%
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)
Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Insider Trades by Quarter for Amgen (NASDAQ AMGN)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/13/2017Sean E HarperEVPSell1,525$171.58$261,659.50View SEC Filing  
11/8/2017Carbonnel Francois DeDirectorSell4,000$173.61$694,440.00View SEC Filing  
10/9/2017Sean E HarperEVPSell1,525$185.95$283,573.75View SEC Filing  
5/24/2017Cynthia M PattonSVPSell2,922$154.40$451,156.80View SEC Filing  
8/2/2016Annette Louise SuchVPSell3,000$174.59$523,770.00View SEC Filing  
5/4/2016Madhavan BalachandranEVPSell30,000$154.12$4,623,600.00View SEC Filing  
4/29/2016David BaltimoreDirectorSell3,312$157.21$520,679.52View SEC Filing  
4/29/2016Sean E HarperEVPSell21,875$157.99$3,456,031.25View SEC Filing  
8/31/2015Carbonnel Francois DeDirectorSell5,000$153.84$769,200.00View SEC Filing  
8/19/2015Fred HassanDirectorBuy3,010$166.63$501,556.30View SEC Filing  
6/2/2015Cynthia M PattonSVPSell4,530$157.06$711,481.80View SEC Filing  
4/23/2015Stuart A TrossSVPSell3,012$169.31$509,961.72View SEC Filing  
4/22/2015Sean E HarperEVPSell28,000$171.58$4,804,240.00View SEC Filing  
3/3/2015Stuart A TrossSVPSell4,415$157.74$696,422.10View SEC Filing  
3/2/2015David BaltimoreDirectorSell3,647$158.76$578,997.72View SEC Filing  
2/11/2015Robert A BradwayCEOSell22,000$152.69$3,359,180.00View SEC Filing  
2/5/2015Frank C HerringerDirectorBuy3,000$152.29$456,870.00View SEC Filing  
12/3/2014Carbonnel Francois DeDirectorSell3,000$168.01$504,030.00View SEC Filing  
8/5/2014Cynthia M PattonSVPSell2,644$127.97$338,352.68View SEC Filing  
8/5/2014Sean E HarperEVPSell14,000$127.29$1,782,060.00View SEC Filing  
5/21/2014Thomas J.W. DittrichCAOSell4,130$112.83$465,987.90View SEC Filing  
4/28/2014A Kelly MichaelCFOSell2,065$110.45$228,079.25View SEC Filing  
3/6/2014Carbonnel Francois DeDirectorSell1,000$126.69$126,690.00View SEC Filing  
9/4/2013Madhavan BalachandranEVPSell18,000$112.76$2,029,680.00View SEC Filing  
8/28/2013David BaltimoreDirectorSell4,582$109.66$502,462.12View SEC Filing  
5/22/2013Thomas J.W. DittrichCAOSell6,130$104.78$642,301.40View SEC Filing  
5/21/2013Madhavan BalachandranEVPSell6,000$103.28$619,680.00View SEC Filing  
5/17/2013Rebecca M HendersonDirectorSell8,421$105.72$890,268.12View SEC Filing  
5/16/2013Cynthia M PattonSVPSell3,544$105.01$372,155.44View SEC Filing  
5/14/2013Judith C PelhamDirectorSell25,000$108.25$2,706,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Amgen (NASDAQ AMGN)

Source:
DateHeadline
Amgen (AMGN) Unveils Auto Injector Device for Enbrel in US ... - NasdaqAmgen (AMGN) Unveils Auto Injector Device for Enbrel in US ... - Nasdaq
www.nasdaq.com - November 21 at 3:15 AM
Earnings Growth Limit Amgen (AMGN) Rating | InvestorPlace - Investorplace.comEarnings Growth Limit Amgen (AMGN) Rating | InvestorPlace - Investorplace.com
investorplace.com - November 21 at 3:15 AM
Inside The GE Dividend Disaster (And Another Sacred Cow To Sell Now)Inside The GE Dividend Disaster (And Another 'Sacred Cow' To Sell Now)
finance.yahoo.com - November 20 at 5:13 PM
Amgen (AMGN) Unveils Auto Injector Device for Enbrel in USAmgen (AMGN) Unveils Auto Injector Device for Enbrel in US
finance.yahoo.com - November 20 at 5:13 PM
Earnings Growth Limit Amgen (AMGN) RatingEarnings Growth Limit Amgen (AMGN) Rating
investorplace.com - November 20 at 12:06 PM
Coherus down 13% on Amgen launch of single-dose cartridge version of EnbrelCoherus down 13% on Amgen launch of single-dose cartridge version of Enbrel
seekingalpha.com - November 17 at 4:50 PM
Amgen Launches The ENBREL Mini™ Single-Dose Prefilled Cartridge With AutoTouch™ Reusable Autoinjector That Is Ergonomically Designed For PatientsAmgen Launches The ENBREL Mini™ Single-Dose Prefilled Cartridge With AutoTouch™ Reusable Autoinjector That Is Ergonomically Designed For Patients
finance.yahoo.com - November 17 at 2:55 PM
Amgen, Inc. : AMGN-US: Dividend Analysis : November 17th, 2017 (record date) : By the numbers : November 17, 2017Amgen, Inc. : AMGN-US: Dividend Analysis : November 17th, 2017 (record date) : By the numbers : November 17, 2017
finance.yahoo.com - November 17 at 2:55 PM
Rare genes yield new hope for managing pain without opioidsRare genes yield new hope for managing pain without opioids
finance.yahoo.com - November 17 at 2:55 PM
Insider Selling: Amgen Inc. (AMGN) EVP Sells 1,525 Shares of StockInsider Selling: Amgen Inc. (AMGN) EVP Sells 1,525 Shares of Stock
www.americanbankingnews.com - November 14 at 11:01 PM
Amgen is OversoldAmgen is Oversold
www.nasdaq.com - November 14 at 4:19 PM
Why Biotech Stocks Are Nearing a ReboundWhy Biotech Stocks Are Nearing a Rebound
finance.yahoo.com - November 14 at 4:19 PM
How Novartis’s Cosentyx Is Positioned after 3Q17How Novartis’s Cosentyx Is Positioned after 3Q17
finance.yahoo.com - November 14 at 4:19 PM
Amgen Gets Positive CHMP Opinion to Expand Nplates LabelAmgen Gets Positive CHMP Opinion to Expand Nplate's Label
www.nasdaq.com - November 14 at 2:43 AM
ETFs with exposure to Amgen, Inc. : November 13, 2017ETFs with exposure to Amgen, Inc. : November 13, 2017
finance.yahoo.com - November 14 at 2:43 AM
New Analyses Presented At AHA 2017 Show Repatha® (evolocumab) Significantly Reduced Cardiovascular Events In Patients With Peripheral Artery Disease And In Patients With A History Of Heart AttacksNew Analyses Presented At AHA 2017 Show Repatha® (evolocumab) Significantly Reduced Cardiovascular Events In Patients With Peripheral Artery Disease And In Patients With A History Of Heart Attacks
finance.yahoo.com - November 14 at 2:43 AM
Earnings Momentum Restrict Amgen (AMGN) RatingEarnings Momentum Restrict Amgen (AMGN) Rating
investorplace.com - November 13 at 11:49 AM
Read This Before Buying Amgen Inc (AMGN) For Its Upcoming $1.15 DividendRead This Before Buying Amgen Inc (AMGN) For Its Upcoming $1.15 Dividend
finance.yahoo.com - November 12 at 3:48 PM
Amgen Gets Positive CHMP Opinion To Expand Use Of Nplate In Pediatric PatientsAmgen Gets Positive CHMP Opinion To Expand Use Of Nplate In Pediatric Patients
www.rttnews.com - November 10 at 7:18 PM
Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate® (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic PurpuraAmgen Receives Positive CHMP Opinion To Expand Use Of Nplate® (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura
finance.yahoo.com - November 10 at 7:18 PM
Short Sellers Grow More Selective on Major Biotechs - 24/7 Wall St.Short Sellers Grow More Selective on Major Biotechs - 24/7 Wall St.
247wallst.com - November 10 at 2:16 PM
Ligand (LGND) Q3 Earnings & Revenues Top, 2017 View RaisedLigand (LGND) Q3 Earnings & Revenues Top, 2017 View Raised
finance.yahoo.com - November 10 at 2:16 PM
Analysts’ Recommendations for Celgene in November 2017Analysts’ Recommendations for Celgene in November 2017
finance.yahoo.com - November 9 at 4:57 PM
Carbonnel Francois De Sells 4,000 Shares of Amgen Inc. (AMGN) StockCarbonnel Francois De Sells 4,000 Shares of Amgen Inc. (AMGN) Stock
www.americanbankingnews.com - November 8 at 6:48 PM
Only a handful of stocks are driving the stock market rally—againOnly a handful of stocks are driving the stock market rally—again
finance.yahoo.com - November 8 at 3:45 PM
Only 7 Days Left To Cash In On Amgen Inc (AMGN) Dividend, Should You Buy?Only 7 Days Left To Cash In On Amgen Inc (AMGN) Dividend, Should You Buy?
finance.yahoo.com - November 8 at 3:45 PM
Consolidated Research: 2018 Summary Expectations for Union Pacific, HCA Holdings, PulteGroup, AmgenConsolidated Research: 2018 Summary Expectations for Union Pacific, HCA Holdings, PulteGroup, Amgen
www.nasdaq.com - November 6 at 4:35 PM
Amgen Announces New Analyses Of High-Risk Patient Subgroups From Repatha® (evolocumab) Cardiovascular Outcomes Study At AHA Scientific Sessions 2017Amgen Announces New Analyses Of High-Risk Patient Subgroups From Repatha® (evolocumab) Cardiovascular Outcomes Study At AHA Scientific Sessions 2017
finance.yahoo.com - November 6 at 4:35 PM
Uninspiring Earnings Momentum Hamper Amgen (AMGN) RatingUninspiring Earnings Momentum Hamper Amgen (AMGN) Rating
investorplace.com - November 6 at 12:22 PM
A Dividend ETF For November And Beyond - BenzingaA Dividend ETF For November And Beyond - Benzinga
www.benzinga.com - November 5 at 3:47 PM
Buy These 7 Dividend Hikes Before Theyre AnnouncedBuy These 7 Dividend Hikes Before They're Announced
finance.yahoo.com - November 5 at 3:47 PM
Amgen Inc. (AMGN) Expected to Announce Quarterly Sales of $5.84 BillionAmgen Inc. (AMGN) Expected to Announce Quarterly Sales of $5.84 Billion
www.americanbankingnews.com - November 5 at 1:52 AM
How Did Amgen’s Enbrel, Nplate, and Vectibix Perform in 3Q17?How Did Amgen’s Enbrel, Nplate, and Vectibix Perform in 3Q17?
finance.yahoo.com - November 3 at 9:35 AM
Amgen And Novartis Announce Expanded Collaboration With Banner Alzheimers Institute In Pioneering Prevention ProgramAmgen And Novartis Announce Expanded Collaboration With Banner Alzheimer's Institute In Pioneering Prevention Program
finance.yahoo.com - November 2 at 9:15 PM
How Did Amgen’s Neulasta and Neupogen Perform in 3Q17?How Did Amgen’s Neulasta and Neupogen Perform in 3Q17?
finance.yahoo.com - November 2 at 4:14 PM
How Are Amgen’s Repatha and Blincyto Positioned after 3Q17?How Are Amgen’s Repatha and Blincyto Positioned after 3Q17?
finance.yahoo.com - November 2 at 4:14 PM
Kirin-Amgen JV To Become Wholly-owned Subsidiary Of Amgen - Quick FactsKirin-Amgen JV To Become Wholly-owned Subsidiary Of Amgen - Quick Facts
www.rttnews.com - November 1 at 9:23 PM
Amgen Inc. -- Moodys assigns Baa1 to Amgens notes; stable outlookAmgen Inc. -- Moody's assigns Baa1 to Amgen's notes; stable outlook
finance.yahoo.com - November 1 at 9:23 PM
Amgen Downgraded After Top Products See Sales Slip In Q3 - BenzingaAmgen Downgraded After Top Products See Sales Slip In Q3 - Benzinga
www.benzinga.com - November 1 at 4:20 PM
Amgen Downgraded After Top Products See Sales Slip In Q3Amgen Downgraded After Top Products See Sales Slip In Q3
finance.yahoo.com - November 1 at 4:20 PM
Amgens One Big ProblemAmgen's One Big Problem
finance.yahoo.com - November 1 at 4:20 PM
ETFs with exposure to Amgen, Inc. : November 1, 2017ETFs with exposure to Amgen, Inc. : November 1, 2017
finance.yahoo.com - November 1 at 4:20 PM
How Did Amgen Perform in 3Q17?How Did Amgen Perform in 3Q17?
finance.yahoo.com - November 1 at 4:20 PM
How Amgen’s Prolia and Xgeva Performed in 3Q17How Amgen’s Prolia and Xgeva Performed in 3Q17
finance.yahoo.com - November 1 at 4:20 PM
How Amgen’s Kyprolis Performed in 3Q17How Amgen’s Kyprolis Performed in 3Q17
finance.yahoo.com - November 1 at 4:20 PM
AMGN Named Top Dividend Stock of the Nasdaq 100 at Dividend ... - NasdaqAMGN Named 'Top Dividend Stock of the Nasdaq 100' at Dividend ... - Nasdaq
www.nasdaq.com - October 31 at 10:03 PM
Head to Head Contrast: Amgen (AMGN) versus Its RivalsHead to Head Contrast: Amgen (AMGN) versus Its Rivals
www.americanbankingnews.com - October 31 at 7:14 PM
Japans Kirin cashes out of Amgen drug joint venture - Reuters - ReutersJapan's Kirin cashes out of Amgen drug joint venture - Reuters - Reuters
www.reuters.com - October 31 at 5:02 PM
Amgen to pay Kirin $780M for ownership of joint ventureAmgen to pay Kirin $780M for ownership of joint venture
seekingalpha.com - October 31 at 7:58 AM
Kirin-Amgen Joint Venture To Become Wholly-Owned Subsidiary Of AmgenKirin-Amgen Joint Venture To Become Wholly-Owned Subsidiary Of Amgen
finance.yahoo.com - October 31 at 2:48 AM

Social Media

Financials

Chart

Amgen (NASDAQ AMGN) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.